Osteochondral repair in synovial joints

Current Opinion in Rheumatology

Volumn 19, Issue 3, 2007, Pages 265-271

  Verbruggen, Gust ^a   Wittoek, Ruth ^a   Groeneboer, Sara ^a   Cruyssen, Bert Vander ^a   Goemaere, Stefan ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Arthritis; Osteochondral repair; Tumor necrosis factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYTOKINE; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICULAR CARTILAGE; AUTOCRINE EFFECT; BONE MARROW CELL; BONE TURNOVER; CARTILAGE CELL; CLINICAL TRIAL; CONNECTIVE TISSUE CELL; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; HOMEOSTASIS; HUMAN; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOID; OSTEOLYSIS; OSTEOPHYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL; STROMA CELL;

ARTHRITIS; CARTILAGE, ARTICULAR; CHONDROGENESIS; CONNECTIVE TISSUE CELLS; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMANS; INTERLEUKIN-1; JOINT DISEASES; MODELS, BIOLOGICAL; OSTEOGENESIS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247103694     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3280be58ff     Document Type: Review

References (63)

1. Moos V, Fickert S, Muller B, et al. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 1999; 26:870-879.
2. Luyten FP, Hascall VC, Nissley SP, et al. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys 1988; 267:416-425.
3. Verbruggen G, Malfait AM, Dewulf M, et al. Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. Osteoarthritis Cartilage 1995; 3:249-259.
4. Yaeger PC, Masi TL, de Ortiz JL, et al. Synergistic action of transforming growth factor-beta and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocytes. Exp Cell Res 1997; 237:318-325.
5. Saklatvala J, Pilsworth LMC, Sarsfield SJ, et al. Pig catabolin is a form of interleulin 1. Biochem J 1984; 224:461-466.
6. Tyler JA, Saklatvala J. Pig IL-1 (catabolin) induces resorption of cartilage proteoglycan and prevents synthesis of proteoglycan and collagen. Br J Rheumatol 1985; 24 (Suppl 1):150-155.
7. Bird TA, Saklatvala J. Identification of a common class of high affinity receptors for both types of interleulin-1 on connective tissue cells. Nature 1986; 324:263-266.
8. Colotta F, Re F, MuzioM, et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993; 261:472-475.
9. Wang J, Elewaut D, Veys EM, Verbruggen G. IGF-1-induced IL-1RII overrules IL-1 activity and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum 2003; 48:1281-1291.
10. Tyler JA. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989; 260:543-548.
11. Ernst M, Froesch ER. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun 1988; 151:142-147.
12. Zhou H, Hammonds RG Jr, Findlay DM, et al. Differential effects of transforming growth factor-beta 1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts. J Cell Physiol 1993; 155:112-119.
13. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602.
14. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
15. Guler HP, Zapf J, Scheiwiller E, Froesch ER. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988; 85:4889-4893.
16. Itoh K, Udagawa N, Matsuzaki K, et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 2000; 15:1766-1775.
17. Chambers TJ, McSheely PM, Thomson BM, Fuller K. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 1985; 116:234-239.
18. Malfait AM, Verbruggen G, Veys EM, et al. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994; 21:314-320.
19. Agarwal S, Deschner J, Long P, et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004; 50:3541-3548.
20. Islam N, Haqqi TM, Jepsen KJ, et al. Hydrostatic pressure induces apoptosis in human chondrocytes from osteoarthritic cartilage through up-regulation of tumor necrosis factor-alpha, inducible nitric oxide synthase, p53, c-myc, and bax-alpha, and suppression of bcl-2. J Cell Biochem 2002; 87:266-278.
21. Redman SN, Dowthwaite GP, Thomson BM, Archer CW. The cellular responses of articular cartilage to sharp and blunt trauma. Osteoarthritis Cartilage 2004; 12:106-116.
22. Shlopov BV, Gumanovskaya ML, Hasty KA. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum 2000; 43:195-205.
23. Wang J, Verdonk P, Elewaut D, et al. Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage 2003; 11:801-809.
24. Pelletier JP, Martel-Pelletier J, Howell DS, et al. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983; 26:63-68.
25. Middleton JF, Tyler JA. Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis 1992; 51:440-447.
26. Penton-Rol G, Orlando S, Polentarutti N, et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. Immunology 1999; 162:2931-2938.
27. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2:244-247.
28. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002; 30:340-346.
29. Kobayashi K, Takahashi K, Jimi E, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191:275-285.
30. Komine M, Kukita A, Kukita T, et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001; 28:474-483.
31. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-290.
32. Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25:255-259.
33. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276:563-568.
34. Zou W, Amcheslavsky A, Takeshita S, et al. TNF-alpha expression is transcriptionally regulated by RANK ligand. J Cell Physiol 2005; 202:371-378.
35. Bhaumick B, Bala RM. Differential effects of insulin-like growth factors I and II on growth, differentiation and glucoregulation in differentiating chondrocyte cells in culture. Acta Endocrinol (Copenh) 1991; 125:201-211.
36. D'Ercole AL, Hill DJ, Strain AJ, Underwood LE. Tissue and plasma somatomedin-C/insulin-like growth factor I concentrations in the human fetus during the first half of gestation. Pediatr Res 1986; 20:253-255.
37. Watanabe N, Rosenfeld RG, Hintz RL, et al. Characterization of a specific insulin-like growth factor-I/somatomedin-C receptor on high density, primary monolayer cultures of bovine articular chondrocytes: regulation of receptor concentration by somatomedin, insulin and growth hormone. J Endocrinol 1985; 107:275-283.
38. McQuillan DL, Handley CJ, Campbell MA, et al. Stimulation of proteoglycan synthesis by serum and insulin-like growth factor-1 in cultured bovine articular cartilage. Biochem J 1986; 240:423-430.
39. Kollewe C, Neumann D, Martin MU. The first two N-terminal immunoglobulin-like domains of soluble human IL-1 receptor type II are sufficient to bind and neutralize IL-1beta. FEBS Lett 2000; 487:189-193.
40. Martel-Pelletier J, Di Battista JA, Lajeunesse D, Pelletier JP. IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis. Inflamm Res 1998; 47:90-100.
41. Olney RC, Wilson DM, Mohtai M, et al. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995; 146:279-286.
42. Sandy JD, Adams ME, Billingham ME, et al. In vivo and in vitro stimulation of chondrocyte biosynthetic activity in early experimental osteoarthritis. Arthritis Rheum 1984; 27:388-397.
43. Carney SL, Billingham ME, Muir H, Sandy JD. Structure of newly synthesised (35S)-proteoglycans and (35S)-proteoglycan turnover products of cartilage explant cultures from dogs with experimental osteoarthritis. J Orthop Res 1985; 3:140-147.
44. Carney SL, Billingham ME, Muir H, Sandy JD. Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis. J Orthop Res 1984; 2:201-206.
45. Sweet MB, Thonar EJ, Immelman AR, Solomon L. Biochemical changes in progressive osteoarthrosis. Ann Rheum Dis 1977; 36:387-398.
46. Manicourt DH, Thonar EJ, Pita JC, Howell DS. Changes in the sedimentation profile of proteoglycan aggregates in early experimental canine osteoarthritis. Connect Tissue Res 1989; 23:33-50.
47. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322:547-549.
48. Sandy JD, Lowther DA, Brown HL. Antigen-induced arthritis. Studies on the inhibition of proteoglycan synthesis observed in articular cartilage during short-term joint inflammation. Arthritis Rheum 1980; 23:433-447.
49. Schalkwijk J, Joosten LA, van den Berg WB, van de Putte LB. Chondrocyte nonresponsiveness to insulin-like growth factor 1 in experimental arthritis. Arthritis Rheum 1989; 32:894-900.
50. Keyszer GM, Heer AH, Kriegsmann J, et al. Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol 1995; 22:275-281.
51. Matsumoto T, Gargoski SE, Iwasaki K, Rosenfeld RG. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996; 81:150-155.
52. Mussener A, Funa K, Kleinau S, Klareskog L. Dynamic expression of transforming growth factor-betas (TGF-beta) and their type I and type II receptors in the synovial tissue of arthritic rats. Clin Exp Immunol 1997; 107:112-119.
53. Neidel J, Blum WF, Schaeffer HJ, et al. Elevated levels of insulin-like growth factor (IGF) binding protein-3 in rheumatoid arthritis synovial fluid inhibit stimulation by IGF-I of articular chondrocyte proteoglycan synthesis. Rheumatol Int 1997; 17:29-37.
54. Nuver-Zwart I, Schalkwijk J, Joosten LA, et al. Effects of synovial fluid and synovial fluid cells on chondrocyte metabolism in short term tissue culture. J Rheumatol 1988; 15:210-216.
55. Partsch G, Petera P, Dunky A, et al. The influence of synovial fluids from patients with rheumatic diseases on chick embryo fibroblasts. Int J Tissue React 1988; 10:67-77.
56. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 1996; 39:308-320.
57. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-1602.
58. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069:420-427.
59. St Clair EW, Van Der Heijde DM, Smolen JS, et al., Active-controlled study of patients receiving Infliximab for the treatment of rheumatoid arthritis of early onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432-3443.
60. Smolen JS, Van Der Heijde DM, St Clair EW, et al., Active-controlled study of patients receiving Infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54:702-710.
61. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al., TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54:1063-1074.
62. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondyloarthritis. Arthritis Rheum 2007; 56:489-497.
63. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61:207-212.